Company

Product

Description

Indication

Status

Genentech, of South San Francisco, a member of the Roche Group

Rituxan (rituximab)

CD20-targeting monoclonal antibody

Granulomatosis with polyangiitis and microscopic polyangiitis

Approved by FDA for use in combination with glucocorticoids in pediatric patients, 2 and older

Intelgenx Corp., of Saint Laurent, Quebec

Rizaport (rizatriptan)

Oral film formulation; 5-HT 1b/d receptor agonist

Migraine

Resubmitted its 505(b)(2) NDA to FDA following April CRL

Sanofi SA, of Paris

Dupixent (dupilumab)

IL-13/4 receptor antagonist

Atopic dermatitis

Health Canada approved for adolescents with moderate to severe AD not adequately controlled with topical therapies

Notes

For more information about individual companies and/or products, see Cortellis.

 

No Comments